Last reviewed · How we verify
EnterobacterJoint Infection
Approved treatments
- Ciprofloxacine · Poitiers University Hospital
- Ceftriaxon · Centre Hospitalier Universitaire Vaudois
- Fortaz · Pai Holdings Pharm
Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death. - Fortaz · Pai Holdings Pharm
Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance. - Noroxin
- Floxin
- Cipro · Bayer AG
- Rocephin · Generic (originally Roche)
- Ceftazidim · Tel-Aviv Sourasky Medical Center
- Ofloxacine · Assistance Publique - Hôpitaux de Paris
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- EnterobacterJoint Infection patent landscape — cliff calendar, originator estates, attackable patents
- EnterobacterJoint Infection treatment landscape brief
- EnterobacterJoint Infection treatment updates RSS
Frequently asked questions about EnterobacterJoint Infection
What drugs treat EnterobacterJoint Infection?
Tracked treatments include Ciprofloxacine, Ceftriaxon, Fortaz, Noroxin, Floxin, Cipro, Rocephin, Ceftazidim.
What is the treatment for EnterobacterJoint Infection?
Standard treatment for EnterobacterJoint Infection includes Ciprofloxacine, Ceftriaxon, Fortaz, Noroxin, Floxin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: EnterobacterJoint Infection patent cliff · EnterobacterJoint Infection CI report
- Treatment: Ciprofloxacine · Poitiers University Hospital
- Treatment: Ceftriaxon · Centre Hospitalier Universitaire Vaudois
- Treatment: Fortaz · Pai Holdings Pharm
- Treatment: Fortaz · Pai Holdings Pharm
- Treatment: Noroxin
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing